Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Non-Current Assets of $26.6 million for Q1 2026, down 52.75% year-over-year from $56.3 million in Q1 2025, and down 11.67% quarter-over-quarter from $30.1 million in Q4 2025.
Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Non-Current Assets for 7 consecutive years, with $26.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 52.75% year-over-year to $26.6 million; the TTM figure through Mar 2026 stood at $124.6 million (down 65.31% YoY), while the FY2025 annual figure was $30.1 million, down 67.92% from the prior year.
- Non-Current Assets eased to $26.6 million in Q1 2026 per CRBU's latest filing, from $30.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $113.5 million in Q4 2022 and bottomed at $26.6 million in Q1 2026.
- Historically, Non-Current Assets has averaged $78.1 million across 5 years, with a median of $91.9 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 611.69% — and 2025, when it slumped 72.18%.
- Caribou Biosciences' Non-Current Assets stood at $113.5 million in 2022, then retreated by 17.75% to $93.4 million in 2023, then rose by 0.61% to $93.9 million in 2024, then slumped by 67.92% to $30.1 million in 2025, then fell by 11.67% to $26.6 million in 2026.
- Business Quant data shows CRBU's Non-Current Assets at $26.6 million in Q1 2026, $30.1 million in Q4 2025, and $39.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 18.06 Bn |
| 10 | Caribou Biosciences | 168.65 Mn | 56.33 Mn | - | 26.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.18 Mn |
| Mar 31, 2026 | 26.62 Mn |
| Dec 31, 2025 | 30.14 Mn |
| Sep 30, 2025 | 39.48 Mn |
| Jun 30, 2025 | 28.40 Mn |
| Mar 31, 2025 | 56.33 Mn |
| Dec 31, 2024 | 93.94 Mn |
| Sep 30, 2024 | 106.91 Mn |
| Jun 30, 2024 | 102.06 Mn |
| Mar 31, 2024 | 102.31 Mn |
| Dec 31, 2023 | 93.37 Mn |
| Sep 30, 2023 | 106.83 Mn |
| Jun 30, 2023 | 81.11 Mn |
| Mar 31, 2023 | 107.97 Mn |
| Dec 31, 2022 | 113.52 Mn |
| Sep 30, 2022 | 91.90 Mn |
| Jun 30, 2022 | 68.44 Mn |
| Mar 31, 2022 | 77.99 Mn |
| Dec 31, 2021 | 51.16 Mn |
| Sep 30, 2021 | 12.91 Mn |